Unique ID issued by UMIN | UMIN000024741 |
---|---|
Receipt number | R000028461 |
Scientific Title | The study regarding screening tests for HIV complications associated with aging in HIV infected patients. |
Date of disclosure of the study information | 2016/11/10 |
Last modified on | 2019/02/20 17:03:37 |
The study regarding screening tests for HIV complications associated with aging in HIV infected patients.
The study of HIV complications and PET
The study regarding screening tests for HIV complications associated with aging in HIV infected patients.
The study of HIV complications and PET
Japan |
HIV infection
Infectious disease |
Malignancy
NO
To find out the possibility of early detection of malignant tumors and dementia associated with aging in HIV infected patients through performing FDG-PET/CT examinations and ancillary tests (e.g. upper gastrointestinal endoscopy, chest CT, tumor marker test, head MRI, neuropsychological test, etc.).
Others
Epidemiology
Exploratory
Pragmatic
Not applicable
Presence of undiagnosed malignant tumor and/or dementia in HIV positive patients with hemophilia.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Other |
Starting November 2016 to end of March 2019, we will conduct two malignant tumor screening tests, including FDG-PET/ CT examination, chest CT examination, upper gastrointestinal endoscopy, blood tumor marker test, stool test, urine test and blood chemistry study with an interval of more than one year in between tests. As a screening test for dementia, we will conduct head MRI, neuropsychological test, and FDG-PET/CT examination (also serves as a malignant tumor screening test) once.
35 | years-old | <= |
Not applicable |
Male
1) HIV infected patients with hemophilia who are 35 years old or older
2) A consent to participate has been obtained in a written form.
1) If an attending physician decides the patient requires urgent treatment
2) A patient with poor control of diabetes (FBS>150mg/dL)
3) A patient with serious underlying disease, which may lead to liver/kidney dysfunction and/or metabolic disorder
4) A patient with mental illness or psychiatric symptoms determined to confront difficulty when participating in the study
5) A patient with history of hypersensitivity to FDG
6) Other patients, whose attending physician has determined inappropriate to participate
50
1st name | |
Middle name | |
Last name | Shinichi Oka |
National Center for Global Health and Medicine
AIDS Clinical Center
1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan
03-3202-7181
oka@acc.ncgm.go.jp
1st name | |
Middle name | |
Last name | Shinichi Oka |
National Center for Global Health and Medicine
AIDS Clinical Center
1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan
03-3202-7181
oka@acc.ncgm.go.jp
AIDS Clinical Center, National Center for Global Health and Medicine
Ministry of Health, Labour and Welfare
Japanese Governmental office
Japan
NO
国立国際医療研究センター(東京都)
2016 | Year | 11 | Month | 10 | Day |
Unpublished
Completed
2016 | Year | 09 | Month | 20 | Day |
2016 | Year | 11 | Month | 15 | Day |
2019 | Year | 02 | Month | 20 | Day |
2016 | Year | 11 | Month | 07 | Day |
2019 | Year | 02 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028461